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Libraries of diverse small molecules are important to probe and drug discovery. The current trend toward
building massive screening collections to support drug development, a special application of chemical
biology, can limit their broader potential. Biology-driven construction methods (Wallace et al., 2011) are
rapidly emerging to bring chemical libraries back on a viable path.When the label of a prescription medicine
reads ‘‘inactive ingredients 98%,’’ it is
telling you the vast majority of substances
in the pills are inert, and that is an impor-
tant and acceptable method of preparing
a drug for administration. However, in
compound libraries designed for chemi-
cal biology, inertness, with apt pharmaco-
kinetics (PK)/pharmacodynamics or not,
is an undesirable filler. Considerable effort
is made to maximize the potential for
bioactivity in modern screening libraries.
Although no one claims to know exactly
which compounds are bioactive in any
particular system, data-driven models
may help select the bright sparks from
the dim bulbs.
The study conducted by Wallace et al.
(2011 [this issue of Chemistry & Biology])
represents an important step toward es-
tablishing a dichotomy between thera-
peutic drug and biological probe discov-
ery. For the most part, probe and drug
development has historically been ap-
proached from the same canonical meth-
odologies and central paradigms. How-
ever, with significantly different goals, it
would seem logical to use divergent paths
and starting points. For example, in library
design, blanket application of Lipinski’s
rule of five (Ro5), and derivatives thereof,
represents the status quo for compoundlibrary selection. Ro5, intended to maxi-
mize the proportion of bioavailable small
molecule agents, has been applied to
guide most commercial and academic
library development (Dolle, 2011). The re-
ality today is that scientists seeking small
molecules as probes to study a target of
interest are relying on compound librar-
ies designed to maximize favorable PK
in human/animal subjects. Compounds
based on peptide-like sequences (Koda-
dek, 2010), privileged structures, and
natural products (Welsch et al., 2010) are
examples of useful chemical probes that
generally fall outside of the Ro5 criteria.
Clearly, the Ro5 along with many other
general compound attributes are desir-
able for therapeutic drug discovery (Over-
ington et al., 2006). Who would want their
drug screening results to be dominated
by unstable molecules with poor PK?
Models developed to guide the popula-
tion of screening libraries are needed, if
not marginally to simplify high-throughput
screening (HTS) logistics and costs, then
importantly to accommodate novel tech-
nology and methodology. In this respect,
the design of chemical libraries is more
valuable than the sheer size. The results
in Wallace et al. (2011) demonstrate, not
unexpectedly, that the Ro5 may not al-
ways be the ideal filter for compoundslikely to be useful in chemical biology.
A completely new set of compound
selection principles may maximize the
chemical space most relevant to non-
or pretherapeutic applications. After all,
the Wright brothers didn’t include a pres-
surized cabin on their flying machine;
why add drag before you even get off
the ground? Wallace and colleagues
move beyond generic property filters to
develop models for bioactive molecule
characteristics. This is an evolving con-
cept in biology-driven library construction
(Basu et al., 2011) that focuses on struc-
tural signatures instead of generic de-
scriptors (such as calculated solubility
partition coefficients, e.g., cLogP and
molecular weight). In an examination of
publicly available screening data sets,
their Bayesian model showed promise in
enriching for the most active hits.
Given the value of probe molecules
to basic research, a fundamental rethink-
ing of the methodologies used in
such efforts is warranted. The Wallace
et al. (2011) presents timely and immedi-
ately useful ideas for chemical biology.
While the academic efforts to develop
therapeutically relevant small molecules
continue to show promise worldwide,
their research to aid in the discovery of
flexible and titratible tools (probes) that
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lations (siRNA, shRNA, zinc finger/
TALEN, cDNA, etc.) holds substantial
promise. As screening capability has
become widespread and less dogmatic,
academic HTS has embraced (to varying
degrees) model organism-based assays
in hosts such as bacteria, yeast, worm,
and zebrafish. Model organisms have
the advantage of accessible, well-charac-
terized biology, expansive tool sets for
assay design, and high degrees of
conservation in many eukaryotic path-
ways allowing for relevant biology to be
explored (Taylor et al., 2010). In this
regard, the authors have utilized yeast
as a basic platform to search for bioactive
small molecules. Interestingly, they find
that compounds with growth modifying
phenotypes in yeast also exhibited
activity in cultured cells from various
eukaryotes.
Compact libraries of compiled bioac-
tive small molecules such as LOAPC
have proven to be of exceptional utility in
chemical biology and are the household
names of HTS and drug discovery. Pres-
ently, even as screening throughput can
easily exceed 100,000 compounds per
day in a modern HTS facility, the value of
small, highly enriched compound librar-
ies remains paramount. As these popular
benchmark libraries have become a
routine part of discovery campaigns, we
should recognize that their existence
was made possible by many years of re-
search. Even though the bioactive library
assembled in Wallace et al. (2011) con-
tains much less annotation than collec-tions such as LOPAC, the authors have
demonstrated a method to accelerate
mechanism-of-action (MOA) elucidation.
Additionally, by leveraging the high
throughput MOA mapping tools offered
by model organisms such as yeast, the
authors outlined a feasible path toward
rapid annotation.
It is critical to realize that the haploinsuf-
ficiency profiling utilized in Wallace et al.
(2011) to understand the basis of growth
phenotype perturbation is just a fraction
of what may be possible (Cong et al.,
2011; Taylor et al., 2010). However, since
cell viability is an inherently general phe-
notypic readout, it is important to empha-
size that there may be potential pitfalls of
such an approach. While profiling tools
help guard against enrichment of un-
wanted artifacts of the chosen readout,
new library construction models must still
establish a proven track record as effec-
tive in delivering useful probes. We ex-
pect that future examples of compound
enrichment schemes will include non-
growth based readouts to strengthen the
methodology.
Looking forward, we foresee new
models of bioactivity enrichment playing
an important role in probe discovery.
Wallace et al. (2011) fits into a larger
framework highlighted by Workman and
Collins: defining the scientific paradigm
of probe development (Workman andCol-
lins, 2010). In light of the Workman and
Collins ‘‘fit-for-purpose’’ definition of a
useful biological probe, it is important to
consider library design as being tailored
to the individual needs of discovery proj-Chemistry & Biology 18, October 28, 2011 ªects. Wallace and colleges have demon-
strated how simple phenotypic screening
of model organisms may be a path to
rapidly build libraries targeting a custom-
fit biology. Today, collections of approved
drugs are the pinnacle of library enrich-
ment for therapeutically endowed com-
pounds (Huang et al., 2011). While these
libraries continue to grow incrementally,
probe-directed collections could achieve
exponential expansion, potentially with
important consequences for the progress
of chemical biology.REFERENCES
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